No need to login to view prices!
|Create new account|
Due to technical maintenance the webshop is closed until January 4th, 2020. We wish you a successful 2021!
Xiamen, China – November 2, 2017 - Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, has announced that Jay Dong, General Manager of its China operations, has been elected Co-President of the Chinese Society for Cell Biology’s Academia-Industry Consortium for Innovation and Entrepreneurship. This consortium was formed to support translation of basic research into translational medicine. Dong was inaugurated by Dr. Yeguang Chen, President of Chinese Society for Cell Biology (CSCB) at CSCB 2018 Conference in Xiamen, China.
As one of the leading industry representatives in the consortium, CST will be an active participant, providing support to local scientists and sharing the company’s experience in moving basic research findings from the bench to the clinic. During the conference, Dong described how CST scientists identified an ALK mutation in non-small cell lung cancer using proprietary PTMScan® technology. This CST discovery has been translated into several companion diagnostic assays used to identify patients that may respond to certain therapeutics for treating non-small cell lung cancer.
“China now ranks among the top nations in the annual quantity and quality of papers published internationally,” said Jay Dong during his inaugural speech. “However, our mission right now is to translate scientific findings into therapeutics that have the potential to aid humankind. The major mission of the consortium is to build a cooperative, complementary relationship between academia and industry, so they can empower the advancement of translational medicine together. There is no easy path or shortcut to translational science, but through cooperation, we can be both small enough to be effective and large enough to be impactful. As for CST, we want to empower scientists to translate their innovative ideas into clinical solutions.”
"Science and business working together benefits all of us, as business brings the experience of turning discoveries into practical realities. We all have the aim of innovating for the benefit of patients and eliminating disease, and we can coordinate our strengths to this result," said Christopher Budde, Chief Commercial Officer and Head of Global Operations of CST.
“To empower, enable scientists around the world to conduct innovative, translational research is part of our CST mission”, commented Michael Comb, CEO of CST.